HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum.
3-[(2,3-Cyclopenteno-1-pyridinium)-methyl]-7-[2-syn-methoximino-2-(2-aminothiazol-4-yl)-acetamido]-ceph-3-em-4-carboxylate (HR 810) is a new cephalosporin derivative with an extremely broad antimicrobial spectrum. It is active against all bacterial species of clinical relevance, including strains which are frequently resistant towards cephalosporins of the third generation.
D001419:Bacteria / Q000187:drug effects*; D001420:Bacteria, Aerobic / Q000187:drug effects; D001421:Bacteria, Anaerobic / Q000187:drug effects; D002439:Cefotaxime / Q000494:pharmacology; D002442:Ceftazidime; D002511:Cephalosporins / Q000494:pharmacology*; D055598:Chemical Phenomena; D002621:Chemistry; D000097572:Cefpirome
D002439:Cefotaxime; D002442:Ceftazidime; D002511:Cephalosporins; D000097572:Cefpirome